Cadaveric Human Growth Hormone–Associated Creutzfeldt-Jakob Disease with Long Latency Period, United States
Year: 2025
Type: article
Study design: Case Report
Abstract: We report a case of iatrogenic Creutzfeldt-Jakob disease (iCJD) after a 48.3-year incubation period in a patient treated with cadaveric human growth hormone. iCJD was pathologically confirmed; genetic analysis was negative for pathogenic mutations. Clinicians should consider iCJD in patients with progressive neurologic signs who had received cadaveric human growth hormone treatment.
Source: Emerging infectious diseases
Authors: Anatevka S. Ribeiro, Andrew B. Wolf, Ellen W. Leschek, Lawrence B. Schonberger, Joseph Y. Abrams, Ryan A. Maddox, Brian S. Appleby, Katie Glisic, Aaron Carlson, Elizabeth Matthews
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W4410817568